$9.45
-1.38-12.74%
Last update: Nov 5, 4:00 PM
Keros Therapeutics Inc
KROSNASDAQ
Keros Therapeutics (KROS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.88 | $-1.24 | $-0.92 | $-0.47 |
| Actual | $-0.70 | $-1.45 | $-1.21 | $-0.86 |
| Surprise | +20.4% | -16.9% | -31.5% | -83.0% |
| Revenue | ||||
| Estimate | $13.8M | $635000 | $2.4M | $4.8M |
| Actual | $40.0M | $0 | $367000 | $385000 |
| Surprise | +189.9% | -100.0% | -84.7% | -92.0% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||
| Consensus | $-1.77 | $-2.10 | $-2.21 |
| Revenue | |||
| Consensus | $452856 | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $-0.70 | $-0.88 | 20.4 % |
| Q2 | Aug 3, 2026 | $-1.45 | $-1.24 | -16.9 % |
| Q1 | May 14, 2026 | $-1.21 | $-0.92 | -31.5 % |
| Q4 | Mar 4, 2026 | $-0.86 | $-0.47 | -83.0 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $40.01M | $13.80M | 189.9 % |
| Q2 | Aug 3, 2026 | $0 | $635.00K | -100.0 % |
| Q1 | May 14, 2026 | $367.00K | $2.40M | -84.7 % |
| Q4 | Mar 4, 2026 | $385.00K | $4.80M | -92.0 % |
